(Q43841698)

27 November 2017

title

Salmeterol 100 microg: an analysis of its tolerability in single- and chronic-dose studies (English)

1 reference

27 November 2017

Shrewsbury S

1

1 reference

27 November 2017

Hallett C

series ordinal

2

1 reference

27 November 2017

publication date

1 December 2001

1 reference

Annals of Allergy, Asthma & Immunology

27 November 2017

published in

1 reference

27 November 2017

volume

87

1 reference

27 November 2017

issue

6

1 reference

27 November 2017

page(s)

465-473

1 reference

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

The bronchoprotective effect of inhaled salmeterol in preschool children: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol in paediatric asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Dose-response study with high-dose inhaled salmeterol in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

A 1-week dose-ranging study of inhaled salmeterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Effect of hydrocortisone on beta-adrenergic receptors in lung membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

The effect of salmeterol on the early- and late-phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Duration and magnitude of action of 50 and 100 micrograms of inhaled salmeterol in protecting against bronchoconstriction induced by hyperventilation of dry cold air in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962259-4

7 January 2021

10.1016/S1081-1206(10)62259-4

Identifiers

DOI

1 reference

27 November 2017

1 reference